Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Slides:

Advertisements

Similar presentations

Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice Ying Wang,

Advertisements

Volume 42, Issue 2, Pages (February 2015)

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,

Volume 15, Issue 2, Pages (February 2007)

Malaria-specific transgenic CD4+ T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody.

Cognate interaction with antigen-specific T cells is required for the response of IgG-type memory B cells. Cognate interaction with antigen-specific T.

Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission Yongjun Tian,

Fig. 4. NASH-driven fibrosis is partly TGF-β–dependent.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Volume 18, Issue 5, Pages (May 2003)

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 4. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist, on anemic rodents. The effects of AVP or d(Leu4Lys8)VP, a specific AVPR1B agonist,

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 4 Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after reovirus treatment. Expression of cleaved caspase 3, PD-L1, and PD-1 in HGGs after.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Type 1 immunity drives metabolic disease but protects against NAFLD

Fig. 4. MATE1 transcription in RCC.

Fig. 7 pDCs are critical for the maintenance of skin fibrosis and for the presence of CXCL4 in the skin. pDCs are critical for the maintenance of skin.

Fig. 4. Expression of HGF in liver ECs cooperates with NOX4 inhibition to enhance engraftment of regenerative hepatocytes. Expression of HGF in liver ECs.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Fig. 3. Genetically engineered PD-L1

Fig. 4. Genetically engineered PD-L1

Fig. 7. ApoMSCs exert immunosuppressive activity in GvHD and elicit IDO in engulfing recipient phagocytes. ApoMSCs exert immunosuppressive activity in.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

IFN-γ induces TNF family ligand protein expression in vitro and in vivo. IFN-γ induces TNF family ligand protein expression in vitro and in vivo. (A and.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

RSV peptide library screen for candidate CD4+ T cell epitopes.

Chen Yao, BS, Sandra M. Zurawski, PhD, Elizabeth S

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 3 Hepatic HBV envelope RNA and protein expression levels in HBVRplRag−/− mice 7 days (1 week) and 8 to 24 weeks after adoptive transfer with WT or.

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut

Fig. 2 Adoptive transfer of adult Ox40−/− splenocytes into adult HBVEnvRag−/− mice alters hepatic inflammation, HBsAg clearance, HBsAb seroconversion,

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Volume 19, Issue 7, Pages (July 2011)

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 1. Exposure to P. duboscqi uninfected sand flies (USFs) induces an anti-saliva immunity that protects NHP from vector-transmitted CL. Exposure to.

Volume 29, Issue 3, Pages (March 2016)

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Volume 21, Issue 1, Pages (January 2017)

Volume 28, Issue 5, Pages (May 2008)

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

NOX-deficient NOD-Ncf1m1J immune system has a reduced capacity to transfer type 1 diabetes (T1D) to immune-deficient hosts. NOX-deficient NOD-Ncf1m1J immune.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 4. Genetically engineered PD-L1

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

by Jean Publicover, Anuj Gaggar, Jillian M

GC reaction is impaired in NOTCH2 knock-in mice.

Identification of a novel population of highly cytotoxic c‐Met‐expressing CD8+ T lymphocytes Day 5 c‐Met+ or c‐Met− CD45.2+ Pmel‐1 CTLs treated with either.

Thymocyte Glucocorticoid Resistance Alters Positive Selection and Inhibits Autoimmunity and Lymphoproliferative Disease in MRL-lpr/lprMice Eva Tolosa,

Presentation transcript:

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to HBV. Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to HBV. (A) Plasma ALT values from young HBVEnvRag−/− mice receiving intraperitoneal injection of 150 μg of OX40 agonist antibody (OX86; open triangles, dashed line) or control IgG (purified rat IgG1 isotype control; closed squares, solid line) on days 0, 3, and 5 after adoptive transfer of WT splenocytes (n = 4). (B) Percentages of CD4+ T cells and TFH cells determined by flow cytometry in liver tissue 8 days after adoptive transfer into 3-week-old HBVEnvRag−/− (left panel) or HBVRplRag−/− (right panel) treated with control IgG (black bars) or OX40 agonist (white bars). Bars represent means ± SEM. Statistical significance was determined using the unpaired two-tailed t test (*P < 0.05 and **P < 0.01; n ≥ 3). (C) Presence of HBsAg in the plasma of young HBVEnvRag−/− mice treated with OX40 agonist (open triangles, dashed line) or control IgG (closed squares, solid line). Statistical significance was determined using the chi-square test (***P < 0.001). Data were pooled from two experiments (n = 8 mice per group total). (D) Presence of HBV-specific T cells was determined using IFN-γ ELISpot 56 days after adoptive transfer of young HBVEnvRag−/− mice injected with OX40 agonist (white bars) or control IgG (black bars). Data are representative of three individual experiments (n = pooled from four mice). (E) IFN-γ ELISpot analysis of HBV-specific T cell responses on liver lymphocytes from mice treated with OX40 agonist that cleared HBsAg (striped bars) or treated with OX40 agonist and did not clear HBsAg (gray bars) (n = pooled from two mice). For (D) and (E), the threshold defining a positive response is ≥2× the baseline (dashed line). (F to H) HBVRplRag−/− or HBVEnvRag−/− mice confirmed to have the serological profile of chronic HBV disease were treated with OX40 agonist (open bars) or control antibody (closed bars) (F) for eight treatments 3×/week or (G and H) at days 84, 87, 89 and 168, 171, 173, 175 after adoptive transfer. Presence of HBV-specific T cells was determined using IFN-γ ELISpot on liver lymphocytes after stimulation with (F) individually defined dominant and subdominant peptide epitopes or (G and H) pools of HBV peptides spanning the entire protein (F) 14 days or (G and H) 122 days after first treatment with OX40 agonist or control IgG (38 days after second treatment and 206 days after adoptive transfer) in (G) HBVEnvRag−/− mice and (H) HBVRplRag−/− mice. Data are representative of two individual experiments (n = pooled from 2–4 mice). Threshold defining a positive response is ≥2× the baseline (dashed line). Jean Publicover et al., Sci Transl Med 2018;10:eaah5766 Published by AAAS